BeiGene’s Brukinsa gets Europe approval for follicular lymphoma (NASDAQ:BGNE)

0


Businessman stamping approved stamp on document in meeting

BrianAJackson/iStock via Getty Images

BeiGene (NASDAQ:BGNE) has received a green light in the EU for Brukinsa (zanubrutinib) to treat relapsed or refractory follicular lymphoma.

Brukinsa was approved for use in combination with obinutuzumab in adult patients who have received at least two prior lines



Source link

Leave A Reply

Your email address will not be published.